The pharmaceutical world is seeing a significant shift in diabetes management with the introduction of GLP-1 transdermal devices. These systems offer a potentially more convenient alternative to subcutaneous administrations of GLP-1 receptor agonists, lessening the need for daily needle pricks. The approach administers the drug directly through … Read More